DoD Prostate Cancer Research Program anticipated funding opportunities for FY23

ASCO, ACS CAN urge Congress to increase federal funding for cancer research

Amidst the latest two-tiered continuing resolution signed by Congress Nov. 15—averting a government shutdown—cancer organizations are urging Congress to increase funding for cancer research.

November 17, 2023

Vol.49 No.43

In Brief

Icahn School of Medicine at Mount Sinai receives $5M NCI grant for NIH Cancer Target Discovery and Development Center

The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai has received a $5 million grant from NCI to establish a center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

November 17, 2023

Vol.49 No.43

In Brief

The Mark Foundation for Cancer Research awards more than $5M in ASPIRE grants

The Mark Foundation for Cancer Research has announced 16 outstanding projects in its latest class of ASPIRE awards, granting more than $5 million for research that aims to answer key feasibility and proof-of-concept questions in an accelerated time frame, and scaling for impact based upon initial success.

November 17, 2023

Vol.49 No.43

Clinical Roundup

187 novel genetic variants linked to prostate cancer, revising what is known about genetic risk

An international collaboration led by USC compiled the most comprehensive list of genetic variants associated with prostate cancer risk through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet.

November 10, 2023

Vol.49 No.42

Funding Opportunities

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

MIB Agents, a pediatric osteosarcoma nonprofit, is accepting applications for its annual OutSmarting Osteosarcoma research grant program. This program was established in 2017 and is awarded to projects focused on moving research forward for osteosarcoma patients.

October 27, 2023

Vol.49 No.40

Clinical Roundup

Phase III PSMAfore trial: Pluvicto demonstrates clinically meaningful rPFS benefit in prostate cancer

In the phase III PSMAfore trial, Pluvicto (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor therapy, compared to a change in ARPI1.

October 27, 2023

Vol.49 No.40

DoD Prostate Cancer Research Program anticipated funding opportunities for FY23

YOU MAY BE INTERESTED IN

ASCO, ACS CAN urge Congress to increase federal funding for cancer research

Icahn School of Medicine at Mount Sinai receives $5M NCI grant for NIH Cancer Target Discovery and Development Center

The Mark Foundation for Cancer Research awards more than $5M in ASPIRE grants

187 novel genetic variants linked to prostate cancer, revising what is known about genetic risk

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

Phase III PSMAfore trial: Pluvicto demonstrates clinically meaningful rPFS benefit in prostate cancer

Renew today!

Subscriber content

Login